Over 40 South Korean companies will export 71.6 billion won worth of dried laver to Japan, up 20.9 percent from a year earlier.
In terms of volume, the deals were 25.1 percent higher from the previous year.
The deals were closed during a videoconference hosted by the Korea Fishery Trade Association (KFTA) and five private Japanese firms.
The amount accounts for nearly 88 percent of total exports by 46 South Korean firms involved.
Dried laver is consumed as a side dish with Korean meals usually roasted with sesame oil and fine salt.
Snacks made of dried laver have become popular among foreigners in recent years.
KFTA has held face-to-face meetings in Tokyo in the previous years but had to conduct a videoconference this year due to the coronavirus pandemic.
The deals with Japan, a major importer for South Korean dried laver, came amid tainted bilateral relations.


Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



